Supervisory board

Hans Schikan, PharmD, chairman

Former CEO of Prosensa.

Mark Vaeck, PhD

CEO of Complix, and former CEO of ActoGeniX and Ablynx.

Brian Bronk, PhD

Head of External Innovation for Rare Diseases at Sanofi.

Lucas de Breed, PhD, MBA

INKEF Capital. 

Karl Rothweiler, MBA

Aglaia Biomedical Ventures. 

Samuel Gerssen, MSc, MBA

Waterman 40 Holding.

Jan-Frans van Giessel, MSc.

Oost NL.